Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

'Normal' is killing us.

Donald Trump is out of the White House. COVID-19 is fading, at least in wealthier nations. The world, they say, is returning to “normal.” That’s the narrative that the corporate media is selling. But there’s a problem: “normal” is destroying our planet, threatening our democracies, concentrating massive wealth in a tiny elite, and leaving billions of people without access to life-saving vaccines amid a deadly pandemic. Here at Common Dreams, we refuse to accept any of this as “normal.” Common Dreams just launched our Mid-Year Campaign to make sure we have the funding we need to keep the progressive, independent journalism of Common Dreams alive. Whatever you can afford—no amount is too large or too small—please donate today to support our nonprofit, people-powered journalism and help us meet our goal.

Please select a donation method:

Indian Court Ruling Victory for Patients Around the World

Amitabh Pal

 by The Progressive

An Indian court just granted a huge victory to the sick all over the planet.

“People in developing countries worldwide will continue to have access to low-cost copycat versions of drugs for diseases like H.I.V. and cancer, at least for a while,” said the front-page lead story in the New York Times on Tuesday. “Production of the generic drugs in India, the world’s biggest provider of cheap medicines, was ensured on Monday in a ruling by the Indian Supreme Court.”

The specific case involved the Swiss pharmaceutical giant Novartis, which unsuccessfully argued that the tinkering it did with its anti-leukemia drug Glivec was worthy of a new patent. At stake was not just access to affordable medicine for leukemia patients but also the survival of the Indian generic industry—the world’s leading manufacturer of low-cost medications.

In 1970, India amended its patent law to have patents awarded only for the processes to make medicines, not for the final products. The ramifications were global.

"India became the ‘pharmacy of the world's poor’ in 1970,” the BBC states. “This allowed its many drug producers to create generic copies of medicines still patent-protected in other countries —at a fraction of the price charged by Western drug firms.”

So, Indian generic drug companies played a huge role in combating the biggest scourge of our time.

“It was only when Indian firms began to make cheap copies of HIV drugs that it became possible more than a decade ago to contemplate the treatment of millions of people in impoverished countries of Africa, where the AIDS epidemic was at its worst,” The Guardian writes.

All this seemed to be in jeopardy when in 2005, India’s parliament, under Western pressure, amended the patent law to comply with World Trade Organization rules. A lot of observers, including me, were worried that this move would mark the death-knell for the availability of affordable drugs around the world. But the Indian judiciary has pleasantly surprised us.

Advocacy groups are delighted.

“This is a huge relief for the millions of patients and doctors in developing countries who depend on affordable medicines from India, and for treatment providers like MSF,” Dr. Unni Karunakara, the head of the Nobel Peace Prize-winning Médecins Sans Frontières (Doctors Without Borders), said. “The Supreme Court's decision now makes patents on the medicines that we desperately need less likely.”

There are worrisome clouds on the horizon, however. The awful 2005 law that the Indian parliament passed tightened patents on drugs made after 1995, and the anti-leukemia drug in question was introduced by Novartis in 1993. The real test will come when cases are heard for drugs developed recently or in the future.

“The million-dollar question is what is going to happen for new drugs that have not yet come out,” says Leena Menghaney of Doctors Without Borders.

At the same time, the U.S. pharmaceutical industry is lobbying fast and furious for trade agreements (such as the proposed TransPacific Partnership) to include the toughest patent protections possible.

But these are looming battles to be fought on another day. For now, millions of people have reason to rejoice.

© 2021 The Progressive
Amitabh Pal

Amitabh Pal

Amitabh Pal is managing editor of The Progressive. He has interviewed the Dalai Lama, Mikhail Gorbachev, Jimmy Carter and John Kenneth Galbraith for the magazine.

Support progressive journalism.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

NY Court Suspends Rudy Giuliani From Practicing Law Over Trump Lies

The court pointed to "demonstrably false and misleading" claims of voter fraud made by former President Donald Trump's lawyer.

Andrea Germanos, staff writer ·

State Court Ruling Called 'Big Step' Toward Holding ExxonMobil Accountable

"By clearing this hurdle, the people of Massachusetts are now one step closer to finally having their rightful day in court, where Exxon will have to answer for its campaign of deception."

Jessica Corbett, staff writer ·

Progressives Say 30-Day Eviction Moratorium Extension 'Not Enough'

"This only puts more pressure on our country to find a permanent solution to the housing crisis," said Rep. Ro Khanna. "We can't keep kicking the can down the road."

Brett Wilkins, staff writer ·

'Sounds Like Fascism': DeSantis Signs Law to Collect Political Views of Professors

The law bars universities from "shielding" students from "offensive" views, raising questions about retaliation for professors who enforce respectful classroom conduct.

Julia Conley, staff writer ·

EPA Inaction Blamed as US Bees Suffer Second Highest Colony Losses on Record

Beekeepers lost nearly half of their colonies between April 2020 and April 2021, according to the Bee Informed Partnership survey.

Andrea Germanos, staff writer ·